Home » Authors » Anette Breindl

Articles by Anette Breindl

NewCo News: Mapreg Takes Microtubule Targeting to Beef Up the Brain

March 5, 2008

By Anette Breindl

Embryonic Stem Cell Inhibitor is Irreplaceable Tumor Suppressor

March 4, 2008

By Anette Breindl

Embryonic Stem Cell Inhibitor is Irreplaceable Tumor Suppressor

March 4, 2008

By Anette Breindl

Glutamate is newest transmitter found to influence platelets

March 1, 2008

By Anette Breindl

IAVI, VaxDesign to Toss HIV Antigen Testing into the Well

Feb. 29, 2008

By Anette Breindl

IAVI, VaxDesign to Toss HIV Antigen Testing into the Well

Feb. 29, 2008

By Anette Breindl

New Connections of Clotting to Inflammation in Sepsis, MS

Feb. 28, 2008

By Anette Breindl

New Connections of Clotting to Inflammation in Sepsis, MS

Feb. 28, 2008

By Anette Breindl

Fake Dendritic Cell Expands T Cells Through Triple Action

Feb. 27, 2008

By Anette Breindl

Fake Dendritic Cell Expands T Cells Through Triple Action

Feb. 27, 2008

By Anette Breindl

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...